ME

Medicon Hellas SAASEX Medicon Stock Report

Last reporting period 30 Jun, 2023

Updated 21 Oct, 2024

Last price

Market cap $B

0.014

Micro

Exchange

ASEX - Athens Stock Exchange

MEDIC.AT Stock Analysis

ME

Neutral

Based on Eyestock quantitative analysis, MEDIC.AT`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

56/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

52.0 %

Undervalued

Market cap $B

0.014

Dividend yield

2.21 %

Shares outstanding

4.42 B

Medicon Hellas SA engages in the business of medical technology. The company is headquartered in Athina, Attiki. The company went IPO on 2001-07-11. Its activities include research and development, production, and import and export of diagnostic products; the development of laboratory information systems; the import and distribution of in vitro diagnostics and automated analytical systems, such as Olympus for clinical chemistry, immunochemistry and lab automation, and Nihon Kohden for hematology, and the provision of cosmetic and body care products, such as make-up, anti-ageing and skin care products under the brand name Miss Beaute. Its laboratory information systems products include: Gi-Lab, which is a management system for medical laboratories; Gi-Maxima, a management program for medical centers, and Gi-Blood, which is an application that helps to connect various blood donation networks. On December 6, 2013, it merged by absorption of its subsidiary, Medicon Ltd.

View Section: Eyestock Rating